15.00
3.85 (34.53%)
| Previous Close | 11.15 |
| Open | 12.98 |
| Volume | 2,272,200 |
| Avg. Volume (3M) | 238,376 |
| Market Cap | 538,024,512 |
| Price / Sales | 2.76 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 |
| Profit Margin | -61.82% |
| Operating Margin (TTM) | -69.52% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 41.10% |
| Total Debt/Equity (MRQ) | 11.49% |
| Current Ratio (MRQ) | 16.73 |
| Operating Cash Flow (TTM) | -35.04 M |
| Levered Free Cash Flow (TTM) | -26.02 M |
| Return on Assets (TTM) | -17.46% |
| Return on Equity (TTM) | -35.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | CeriBell, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.88 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 9.97% |
| % Held by Institutions | 82.03% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 31 Dec 2024 | 2,205,661 |
| Yu Fan | 31 Dec 2024 | 1,222,202 |
| Abg-Wtt Global Life Science Capital Partners Gp Ltd | 31 Dec 2024 | 1,088,101 |
| Board Of Trustees Of The Leland Stanford Junior University | 31 Dec 2024 | 623,751 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Canaccord Genuity, 120.00%) | Buy |
| Median | 32.50 (116.67%) | |
| Low | 32.00 (Ladenburg Thalmann, 113.33%) | Buy |
| Average | 32.50 (116.67%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 21.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ladenburg Thalmann | 04 Apr 2025 | 32.00 (113.33%) | Buy | 18.44 |
| Canaccord Genuity | 26 Feb 2025 | 33.00 (120.00%) | Buy | 25.20 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |